Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,312,964 shares of the company’s stock after acquiring an additional 20,864 shares during the period. Geode Capital Management LLC owned about 1.84% of Zentalis Pharmaceuticals worth $3,979,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC grew its holdings in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares during the period. SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after purchasing an additional 30,240 shares during the period. Savant Capital LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $72,000. Ieq Capital LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $46,000. Finally, Anfield Capital Management LLC grew its holdings in Zentalis Pharmaceuticals by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock valued at $392,000 after purchasing an additional 64,659 shares during the period.

Zentalis Pharmaceuticals Stock Down 5.3 %

NASDAQ:ZNTL opened at $1.43 on Monday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $13.24. The company has a market capitalization of $102.69 million, a P/E ratio of -0.57 and a beta of 1.80. The stock’s fifty day moving average is $1.66 and its two-hundred day moving average is $2.50.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. Sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZNTL has been the topic of several research analyst reports. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Finally, UBS Group reduced their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.24.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.